

Artrya appoints Clayton Hatch as Chief Financial Officer

Former CFO of Pro Medicus to provide significant industry scale up expertise

PERTH, Australia, 18 May 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to announce the appointment of Mr Clayton Hatch as Chief Financial Officer effective from 1 September 2026.

Clayton brings more than 25 years of strategic financial, accounting, and operational experience across the Australian and global hospital and radiology sectors. His background in high-growth ASX-listed companies further strengthens Artrya's financial and commercial leadership as the Company enters its next phase of growth.

Clayton served as Chief Financial Officer of Pro Medicus Limited (ASX: PME) from June 2012 to March 2026. During his tenure, Pro Medicus established itself as a global leader in medical imaging software, with a strong focus on North American hospital networks, and grew into an ASX 50 company. As a member of the senior leadership team, Clayton was responsible for financial management, compliance, and investor relations.

Clayton is a Certified Practising Accountant and holds a Bachelor of Commerce from Curtin University and an MBA from Monash Business School.

Artrya also thanks Richard Jarvis for his contribution as interim Chief Financial Officer. Richard will continue in the role during the transition period to support an orderly handover of the finance function.

John Konstantopoulos, Co-Founder and CEO of Artrya, commented:

"I am excited to welcome Clayton to Artrya at this important stage of our commercialisation journey. His extensive experience leading the financial operations of a healthcare IT company that is delivering advanced radiology solutions into the same North American hospital market we are targeting, will be highly valuable to the Company.

Having played a key role in scaling a business from early commercial deployment to a market-leading, multi-billion dollar ASX-listed company, Clayton brings significant financial, commercial, and operational expertise. I also look forward to working closely with Clayton as we continue to expand our investor engagement activities."

Clayton Hatch, incoming CFO of Artrya, commented:

"I am delighted to have the opportunity to become a part of the Artrya team and support the business as it builds out its customers and commercial operations in the U.S. I am also excited by the new opportunities that this AI powered Salix® platform brings to hospitals and clinicians, and the significant revenue opportunities in front of the business.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For personal use only